Jeffrey Iliffe appointed as Chief Financial Officer

Abcam has appointed Jeffrey Iliffe, a highly experienced finance professional with a track record in the City, the healthcare industry and in e-commerce as its new Chief Financial Officer. Mr Iliffe, who has been working as a financial consultant at Abcam for the past 4 months, will join the Company’s Board on 20 November 2007.

Mr Iliffe’s appointment is the result of a planned succession in which, as previously announced, Eddie Powell will leave the Company on 20 November 2007 after almost eight years as Chief Financial Officer.

Jeffrey Michel Iliffe, age 45, is a qualified accountant who worked as a corporate financier in life sciences at Panmure Gordon & Co between 1989 and 1996. He then moved into industry, holding a number of financial positions at companies including the environmental consultancy Enviros Group Limited and the biotechnology company Plethora Solutions plc. Prior to joining Abcam as a financial consultant, he was chief financial officer at St Minver Limited, an e-commerce company that operates online gaming networks.

Mr Iliffe’s broad financial experience, including acquisitions, business integration and investor relations, is expected to be of significant value to Abcam as the Company continues to execute its strategy to become the world’s largest online antibody resource.

David Cleevely, Abcam’s Chairman, said: “I am delighted to announce the appointment of Jeff Iliffe as Chief Financial Officer and to welcome him to Abcam’s Board. I have worked closely with Jeff for the past four months and have been very impressed by his energy and ability. His broad financial experience, combined with his specific knowledge of e-commerce, means that he is ideally qualified to make an important contribution to the ongoing development of the Company.”

Same day delivery in Cambridge UK

Abcam is now offering same day delivery for scientists ordering from Cambridge in the UK!

  • Orders must be placed by 12 noon (UK time)
  • To all addresses in Cambridge UK
  • No extra cost to you!

We are working with local courier firm Outspoken Delivery to ensure that your antibodies and reagents get to you even faster and in the most environmentally friendly way possible. Using specially designed bicycles, your antibodies will get across town much faster through the Cambridge traffic and at no cost to the environment.

Same day environmentally friendly delivery in Cambridge
Molly thinks bikes are best!

The new delivery service means our products will get to you faster in the best possible condition. Our boxes contain protective packaging and ice packs so that your antibodies are kept at the right temperature and protected however they are shipped to you. All products are guaranteed by our Abpromise of 100% support.

Over 30,000 products in our catalog

And still growing! Abcam is working hard to provide everything your research needs

The Abcam team is working hard, adding new products every day and adding new information to the datasheets of existing products. In March 2007 we reached the landmark of having over 30,000 products in our catalog. For our customers this means:

  • More antibody targets
  • More product types
  • More choice

Browse our catalog now

Don’t forget: we don’t just supply antibodies!

Check out our range of product types below. Every item is guaranteed with our Abpromise and has a full datasheet telling you everything we know about that product.

Abcam to partner in the EPITRON project

Abcam is pleased to announce its participation in the EPIgenetic TReatment Of Neoplastic disease (EPITRON) project, as a partner and collaborator. EPITRON is funded by the European Union under the 6th Framework Programme. This multi-disciplinary consortium will define ‘epigenetic’ alterations between cancer and healthy cells and work to develop an entire pipeline of novel therapeutic targets for the treatment of cancer that are based on ‘epigenetics’.

‘Epigenetic’, or non-gene factors, control which regions of our DNA are expressed.  Over our lifetime, epigenetic changes can alter the expression of genes and effect their regulation.  Sometimes these epigenetic changes can be lost and subsequently alter the expression of genes called tumor suppressors that regulate cell growth.  Alterations in tumor suppressors can lead to increased cell growth and the onset of cancer.

Comprising ten academic research groups, three small enterprise companies and one pharmaceutical company, the consortium have strengths and expertise in basic research and also drug development and design. Together the EPITRON consortium is working towards the generation of novel ‘epi-drugs’ to target and regulate the epigenetic makeup of the cell and reprogram cancer cells to normal cells.

EPITRON consortium website

Abcam’s contribution within EPITRON:

Abcam is dedicated to providing high quality antibodies for the EPITRON consortium. New EPITRON antibody projects are being initiated every month and since November 2005 over 120 projects have commenced. These antibodies will at a later date become available to the wider scientific community though Abcam’s website. Abcam’s antibody contribution to the consortium will assist the researchers in reaching its goal to “pave the way to novel types of cancer therapy”.

Abcam has installed a NEW Xpress high-throughput chromatography apparatus enabling high-quality affinity purification of antibodies as well as establishing a dedicated in-house EPITRON team that will characterize all the antibodies.

Abcam Chromatin resources

$2 to Médecins Sans Frontières for every new registration

Create an Abcam account in January and we’ll donate $2 to MSF

medecins_sans_frontiers.jpg

For every new scientist that registers on our website in January we will give $2 to Médecins Sans Frontières (MSF).

** Register now! **

Simply fill in the short online form with your details. It should only take only 1-2 minutes. This will create your own personal Abcam account, allowing you to subscribe to our free email update service and personalise your emails to your specific interest areas. It also allows you to claim Abpoints for purchases or customer reviews (Abreviews) of our antibodies.

Tell your friends too!

We will donate $2 to MSF for every new registration in January, up to a maximum of $2000.

Médecins Sans Frontières (MSF) is an international humanitarian medical aid organisation committed to providing medical aid wherever needed, regardless of race, religion, politics or sex. In carrying out humanitarian assistance, MSF seeks also to raise awareness of the crisis situations of the people they help.

Extra Abpoints introduced for first Abreviews

  • Up to 300 Abpoints now available for each Abreview! 

In an effort to increase the number of customer reviews (Abreviews) for antibodies with little or no customer feedback, extra Abpoints are now available for reviewing these antibodies. Scientists can earn between 50 and 300 Abpoints for each Abreview. The number of Abpoints awarded now depends on when the last Abreview had been submitted for that particular antibody. The less characterised the antibody, the more Abpoints they receive.

More about variable Abpoints for Abreviews

About Abpoints and the Abcam customer loyalty scheme

Appointment of Non-Executive Directors

Abcam has appointed two additional Non-Executive Directors to its board: Timothy George Dye and Mark John Alexander Webster.

Tim Dye, age 43, is currently Chairman and Chief Executive of William Ransom & Son plc, an AIM quoted healthcare company, as well as being a director of Noble Troy Ltd. Over the past six years, and through a series of successful acquisitions, he has led the transformation of William Ransom into one of the UK’s largest natural healthcare groups. Prior to William Ransom, Tim built and ran privately held companies in automated meter reading, environmental management and property development.

Mark Webster, age 44, is a highly experienced pharmaceutical executive who has held senior management positions at Bayer, Shire Pharmaceuticals and Abbott Laboratories. Most recently he was Senior Vice President, Head of Global Strategic Marketing and Licensing / Acquisitions at Bayer Pharmaceuticals.

Commenting on today’s announcement, Jonathan Milner, Abcam’s Chief Executive Officer, said: “I am pleased to welcome both Tim and Mark to Abcam’s Board. Their experience, both in business and in the international pharmaceutical industry, will be of significant value to the Company as we continue to deliver our strategy of becoming the world’s leading research antibody supplier.”

Winner of Best Newcomer in the European Mediscience awards

The European Mediscience awards dinner, held annually in June, recognises and rewards excellence within the quoted life-sciences sector, while also providing a forum for the mediscience industry and the City to meet in a relaxed and convivial atmosphere. The event was sponsored by Evolution Securities, in association with the London Stock Exchange and the BioIndustry Association and has grown in line with the rapid development of the quoted company sector, and this year was again open to AIM companies, as well as those on the Full List. This reflects the growing importance of AIM to both the quoted company and the life-sciences sector as a whole.

Abcam was awarded the prize of “Best Newcomer”. This particular category, sponsored by McGrigors was available to companies that went public in the period under review (1 April 2005 to 31 March 2006) on either the Full List or on AIM. The company should have already demonstrated exceptional investment and growth qualities.

Jonathan Milner accepting Best Newcomer award

best newcomer
Left to right; Kate Silverton (presenter); Jonathan Milner, Abcam plc, (winner); David Mandell, McGrigors; and Andrew Umbers, Evolution Securities.

Better antibodies, faster

  • Our new automated storage and retrieval system has many benefits for you…

We have recently implemented a new storage and retrieval system to enable us to further improve the excellent reliability of our antibodies which is the core of our Abpromise. It will also enable us to despatch products faster with greater accuracy, thus enabling us to get more of your purchases out the same-day.

System details
Specifically, the unit is hermetically sealed with an inert atmosphere & maintains a constant temperature environment, ensuring stable storage.

This new system enables us to use even higher-quality microtubes to contain our antibodies which have the added benefit of being 2D barcoded. They are made of highly polished high-density plastic. We also have new boxes to hold these tubes during shipment. We have taken time to design the box to hold combinations of new and existing tubes. Being scientists, we thought that it would be even more helpful if the box could also function as a benchtop mini-rack, so when you receive one of these boxes simply flip the front cover round as far as possible and the box becomes a rack.

As with any liquid product, it’s important to spin / centrifuge upon receipt. We suggest that you follow standard centrifuge procedure for smaller vials and place them within a microcentrifuge tube before centrifuging. We also recommend that you centrifuge at 12k rpm for at least 20 seconds.

Winner of Private Company of the Year, Business Weekly East of England Business Awards 2005

Just days before floating on the London exchange, Abcam was named Private Company of the Year in the East of England Business Awards 2005. Run by Business Weekly, the awards were sponsored by Eversheds, Deloitte, Lloyds TSB Corporate, UK Trade & Investment BAA Stansted and Opportunity Peterborough.

Chief Executive Jonathan Milner flew in from Taiwan to accept the Award – a a Steuben crystal obelisk.